Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Qi, Q., Lu, L., Li, H., Yuan, Z., Chen, G., Lin, M. & Zhao, Q. (2017). International journal of nanomedicine 12 (2017): 4835

The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated as one of the most promising protein candidates in cardiac regeneration. A significant challenge to the therapeutic use of this protein is its short half-life in vivo. In this study, we evaluated the therapeutic effects and long-term retention of liraglutide loaded in poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles (NP-liraglutide) on experimental MI. PLGA-PEG nanoparticles (NPs) have been shown to efficiently load liraglutide and release bioactive liraglutide in a sustained manner. For in vitro test, the released liraglutide retained bioactivity, as measured by its ability to activate liraglutide signaling pathways. Next, we compared the effects of an intramyocardial injection of saline, empty NPs, free liraglutide and NP-liraglutide in a rat model of MI. NPs were detected in the myocardium for up to 4 weeks. More importantly, an intramyocardial injection of NP-liraglutide was sufficient to improve cardiac function (P<0.05), attenuate the infarct size (P<0.05), preserve wall thickness (P<0.05), promote angiogenesis (P<0.05) and prevent cardiomyocyte apoptosis (P<0.05) at 4 weeks after injection without affecting glucose levels. The local, controlled, intramyocardial delivery of NP-liraglutide represents an effective and promising strategy for the treatment of MI.

Products Used in this Publication

Cat. # Product Name Price
10-101-59 Liraglutide Inquiry

Related Products

Cat. # Product Name Price
10-101-158 Albiglutide Inquiry
CAD-111 GLP-1(7-36)-Lys(6-FAM) amide (human, bovine, guinea pig, mouse, rat) Inquiry
G05010 Oxyntomodulin / Glucagon 37 Inquiry
G16007 Glucagon-Like Peptide II, rat Inquiry
Contact Us

USA

Address:

Tel: |

Email:

Germany

Address:

Copyright © 2024 Creative Peptides. All rights reserved.